The Value of the UroVysion® Assay for Surveillance of Non-Muscle-Invasive Bladder Cancer

European Urology

Volumn 54, Issue 2, 2008, Pages 402-408

  Gudjónsson, Sigurdur ^a   Isfoss, Björn L ^a   Hansson, Kerstin ^a   Domanski, Anna Maria ^a   Warenholt, Janina ^a   Soller, Wolfgang ^a   Lundberg, Lena Maria ^a   Liedberg, Fredrik ^a   Grabe, Magnus ^a   Månsson, Wiking ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bladder cancer; Cystoscopy; Cytology; FISH; Follow up; Sensitivity; Specificity; Surveillance

Indexed keywords

MITOMYCIN C;

ARTICLE; ASSAY; BLADDER BIOPSY; BLADDER CANCER; CONTROLLED STUDY; CYSTOSCOPY; EQUIPMENT; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE; BLADDER TUMOR; CANCER INVASION; HEALTH SURVEY; PATHOLOGY; PROSPECTIVE STUDY;

FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM INVASIVENESS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 45849126870     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.11.051     Document Type: Article

References (23)

1. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477 (discussion 475-7)
2. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., and Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21 (2003) 1315-1330
3. Schmidbauer J., Witjes F., Schmeller N., Donat R., Susani M., and Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 171 (2004) 135-138
4. Black P.C., Brown G.A., and Dinney C.P. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 24 (2006) 5528-5535
5. Bubendorf L., Grilli B., Sauter G., Mihatsch M.J., Gasser T.C., and Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 116 (2001) 79-86
6. Sokolova I.A., Halling K.C., Jenkins R.B., et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2 (2000) 116-123
7. Halling K.C., King W., Sokolova I.A., et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164 (2000) 1768-1775
8. Placer J., Espinet B., Salido M., Solé F., and Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 42 (2002) 547-552
9. Sarosdy M.F., Schellhammer P., Bokinsky G., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168 (2002) 1950-1954
10. Varella-Garcia M., Akduman B., Sunpaweravong P., Di Maria M.V., and Crawford E.D. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol 22 (2004) 16-19
11. Laudadio J., Keane T.E., Reeves H.M., et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int 96 (2005) 1280-1285
12. Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 3 (2003) 507-519
13. Moonen P.M.J., Merkx G.F.M., Peelen P., Karthaus H.F.M., Smeets D.F.C.M., and Witjes J.A. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 51 (2007) 1275-1280 discussion 1280
14. Boman H., Hedelin H., and Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 167 (2002) 80-83
15. Nieder A.M., Soloway M.S., and Herr H.W. Should we abandon the FISH test?. Eur Urol 51 (2007) 1469-1471
16. Veeramachaneni R., Nordberg M.L., Shi R., Herrera G.A., and Turbat-Herrera E.A. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol 28 (2003) 301-307
17. Skacel M., Fahmy M., Brainard J.A., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169 (2003) 2101-2105
18. Zellweger T., Benz G., Cathomas G., et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 119 (2006) 1660-1665
19. Bollmann M., Heller H., Bankfalvi A., Griefingholt H., and Bollmann R. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?. BJU Int 95 (2005) 1219-1225
20. Krause F.S., Rauch A., Schrott K.M., and Engehausen D.G. Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays?. World J Urol 24 (2006) 418-422
21. Pycha A., Lodde M., Comploj E., et al. Intermediate-risk urothelial carcinoma: an unresolved problem?. Urology 63 (2004) 472-475
22. Mian C., Lodde M., Comploj E., et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 59 (2006) 984-987
23. Kipp B.R., Karnes R.J., Brankley S.M., et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 173 (2005) 401-404